Companies › Gan & Lee Pharmaceuticals.
8 active drug programs in 25 registered trials: 11 Phase 3, 8 Phase 1, 4 Phase 2, 2 Phase 4; Metabolic and endocrine, Cardiovascular, Genitourinary, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GZR4 GLP-1 receptor agonist | GLP1R | Phase 3 | Diabetes | Nov 2026 |
| GZR18 injection GLP-1 receptor agonist | – | Phase 3 | Obesity/Overweight; Type 2 Diabetes Mellitus (T2DM); Obesity/Overweight in Adult; Overweight or Obesity … | Dec 2026 |
| GZR33 Injection | – | Phase 3 | Type 2 Diabetes (T2DM) | Apr 2027 |
| Bempedoic Acid ATP-citrate synthase inhibitor | ACLY | Phase 3 | Primary Hyperlipidemia; Acute Coronary Syndromes; Rheumatoid Arthritis (RA); Dyslipidemias … | – |
| GZR102 | – | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Jan 2027 |
| GZC8072 Tablets | – | Phase 1 | Healthy Subjects;Overweight or Obesity | Aug 2027 |
| GZR33 Long-acting basal insulin analogue | INS | Phase 1 | Type 1 Diabetes Mellitis | – |
| Insulin Degludec Insulin receptor agonist | INSR | Phase 1 | Type 2 Diabetes | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07141030 | GZR18 injection | Phase 1 | Obesity/Overweight | Metabolic and endocrine | Oct 2025 |
| NCT06780410 | Bempedoic Acid | Phase 3 | Primary Hyperlipidemia | Metabolic and endocrine | Oct 2025 |
| NCT06767748 | GZR4 | Phase 3 | Diabetes | Metabolic and endocrine | Feb 2026 |
| NCT07242664 | GZR33 | Phase 1 | Type 1 Diabetes Mellitis | Metabolic and endocrine | Feb 2026 |
| NCT06767761 | GZR4 | Phase 3 | Diabetes | Metabolic and endocrine | Mar 2026 |
| NCT07146347 | Insulin Degludec | Phase 1 | Type 2 Diabetes | Metabolic and endocrine | Apr 2026 |
| NCT06728124 | GZR18 injection | Phase 3 | Obesity/Overweight | Metabolic and endocrine | May 2026 |
| NCT07355738 | GZR18 injection | Phase 1 | Obesity&T2D | Metabolic and endocrine | May 2026 |
| NCT07128888 | GZR18 injection | Phase 1 | Obesity or Overweight | Metabolic and endocrine | Jul 2026 |
| NCT07193147 | GZR4 | Phase 1 | Diabetes | Metabolic and endocrine | Jul 2026 |
| NCT06767735 | GZR4 | Phase 3 | Diabetes | Metabolic and endocrine | Aug 2026 |
| NCT07165223 | GZR4 | Phase 3 | Diabetes | Metabolic and endocrine | Nov 2026 |
| NCT06778967 | GZR18 injection | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Dec 2026 |
| NCT07055386 | GZR18 injection | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Jan 2027 |
| NCT07055386 | GZR102 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Jan 2027 |
| NCT07144098 | GZR18 injection | Phase 1 | Obesity/Overweight | Metabolic and endocrine | Jan 2027 |
| NCT06777238 | GZR18 injection | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Mar 2027 |
| NCT07527078 | GZR33 Injection | Phase 3 | Type 2 Diabetes (T2DM) | Metabolic and endocrine | Apr 2027 |
| NCT07150975 | GZR18 injection | Phase 3 | Obesity/Overweight in Adult | Metabolic and endocrine | Jun 2027 |
| NCT07784699 | GZC8072 Tablets | Phase 1 | Healthy Subjects;Overweight or Obesity | Metabolic and endocrine | Aug 2027 |
| NCT07292441 | GZR18 injection | Phase 3 | Overweight or Obesity | Metabolic and endocrine | Sep 2027 |
| NCT05488431 | Bempedoic Acid | Phase 2 | Dyslipidemias | Cardiovascular | Mar 2028 |
| NCT07824323 | Bempedoic Acid | Phase 4 | Acute Coronary Syndromes | Cardiovascular | Mar 2028 |
| NCT07282821 | Bempedoic Acid | Phase 2 | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Genitourinary | Sep 2029 |
| NCT07611747 | Bempedoic Acid | Phase 4 | Rheumatoid Arthritis (RA) | Immunology | Apr 2031 |
Beijing QL Biopharmaceutical Viking Therapeutics Ascletis Pharma (China) The United Bio-Technology (Hengqin) Chendu DIAO Pharmaceutical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.